Role of Uremic Toxins in Mild Cognitive Impairment in Chronic Kidney Disease (MOMENTUM)
Investigator-initiated, Multicentre, International, Cross-sectional and Longitudinal Clinical Study Elucidating the Pathophysiology of Mild Cognitive Impairment in Chronic Kidney Disease With a Focus on the Role of Uremic Toxins
MOMENTUM is an investigator-initiated, multicentre, international, controlled, cross-sectional and longitudinal clinical study, which aims to evaluate the association between plasma levels of UTs and the presence and severity of cognitive impairment, and their mechanistic interplay in study participants with CKD at different disease stages.
The study consists of three main phases: a screening period, a cross-sectional (baseline) phase, and an 18-month follow-up (longitudinal phase).
研究概览
地位
条件
干预/治疗
- 行为的:MoCA Test
- 诊断测试:Laboratory tests
- 诊断测试:Non-contrast-enhanced brain MRI
- 行为的:Comprehensive neuropsychological test battery
- 行为的:Kidney Disease Quality of Life Instrument (KDQOL), KDQOL-SF™ v1, first section
- 行为的:Kidney Disease Quality of Life Instrument (KDQOL), KDQOL-SF™ v1, other sections
- 行为的:Questionnaires
- 行为的:New MCI-CKD QoL Questionnaire
详细说明
Chronic kidney disease (CKD) represents a major and growing global health challenge, affecting over 800 million people worldwide across stages. Its prevalence is increasing due to rising rates of diabetes, hypertension, and obesity, the most common causes of CKD, and the disease is projected to become the fifth leading cause of death by 2040. CKD has been recently prioritized within the WHO noncommunicable diseases agenda in alignment with the United Nation's Sustainable Development Goal (SDG) 3.4 and 3.8. Beyond its direct contribution to morbidity and mortality and its established role as a major risk factor for cardiovascular disease, CKD also significantly impacts neurological health.
Cognitive impairment - particularly Mild Cognitive Impairment (MCI) - is increasingly recognized as a frequent but underexplored complication, occurring at more than twice the rate observed in age-matched individuals from the general population. MCI markedly increases the risk of progression to dementia, and is associated with substantial consequences for patients, caregivers, healthcare systems, and society, highlighting the importance of early identification and intervention.
Despite its clinical and societal importance, MCI-CKD remains an under-recognized health challenge. Its pathophysiological mechanisms are poorly understood, no specific biomarkers have been validated to support diagnosis or prognosis, and no established guidelines exist for its systematic monitoring or management. Most patients remain unaware of the condition, and healthcare providers often overlook it. This lack of awareness and diagnostic capacity hampers timely interventions, including referrals for symptomatic treatments, cognitive rehabilitation strategies, or preventive measures.
As a transitional stage preceding clinical dementia, early identification of MCI-CKD may allow nephrologists to refer patients to neurologists for symptomatic treatments and cognitive rehabilitation strategies.18 Patients diagnosed with MCI-CKD may also be referred for other interventions addressing other modifiable drivers of MCI, such as sleep, stress, dietary habits, exercise and cardiovascular disease.
Clinically, CKD is characterized by a progressive decline in kidney function, typically assessed by the glomerular filtration rate (GFR), which can be estimated through equations based on serum creatinine, cystatin C, or a combination of both (eGFR), or directly measured using exogenous filtration markers such as iohexol or iothalamate clearance (mGFR). Additional indicators of kidney damage include blood urea nitrogen (BUN) levels, the urinary albumin-to-creatinine ratio (ACR), and histological findings from kidney biopsy. However, accurately quantifying nephron loss and the extent of renal fibrosis remains challenging. As kidney function declines, disturbances develop in electrolyte, water, acid-base, and mineral homeostasis. Uremic toxins (UTs) accumulate, and renal anaemia emerges. Several CKD-related factors, including metabolic alterations, inflammation, vascular dysfunction, and UT accumulation, have been independently associated with an increased risk of cognitive impairment.
The MOMENTUM cross-sectional and longitudinal clinical study is designed to address this critical gap. By comprehensively characterizing cognitive impairment in CKD and integrating multimodal biomarkers, including circulating and microbiome-derived uremic toxins, advanced neuroimaging, and clinical assessments, it aims to improve early detection and risk stratification of MCI-CKD. This knowledge will contribute to a better understanding of disease mechanisms, support earlier diagnosis, and enable the development of targeted strategies to reduce cognitive decline and dementia burden in individuals with CKD.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Matias Trillini, M.D.
- 电话号码:+390354535411
- 邮箱:matias.trillini@marionegri.it
学习地点
-
-
-
Naples、意大利、80131
- AOU University of Campania "Luigi Vanvitelli"
-
接触:
- Alessandra Perna
- 电话号码:+390815666822
- 邮箱:alessandra.perna@unicampania.it
-
-
BG
-
Ranica、BG、意大利、24020
- Clinical Research Centre for Rare Diseases Aldo e Cele Daccò
-
接触:
- Matias Trillini, M.D.
- 电话号码:+390354535411
- 邮箱:matias.trillini@marionegri.it
-
-
-
-
-
Lausanne、瑞士、1005
- Centre Hospitalier Universitaire Vaudois
-
接触:
- Menno Pruijm, Prof.
- 电话号码:+41(0)213141131
- 邮箱:Menno.Pruijm@chuv.ch
-
-
-
-
-
Derby、英国、DE22 3NE
- University Hospitals of Derby and Burton NHS Foundation Trust
-
接触:
- Nicholas Selby
- 电话号码:+44(0)1332724665
- 邮箱:nicholas.selby@nottingham.ac.uk
-
-
-
-
-
Pamplona、西班牙、31008
- Clínica Universidad de Navarra
-
接触:
- Nuria Garcia Fernandez, MD PhD
- 电话号码:+34948255400
- 邮箱:nrgarcia@unav.es
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria
- Male or female aged 40-75 years at time of screening;
- Availability for longitudinal follow-up;
- Signed informed consent
Specifically for CKD participants:
- CKD stage G3a/G3b, or stage G4-G5 without kidney replacement therapy, or stage G5 undergoing hemodialysis (HD) for more than 3 months;
- MoCA score in the range [18-25];41
Specifically for controls:
-
Normal renal function:
- For controls aged < 65 years, eGFR ≥ 90 mL/min/1.73 m2;
- For controls aged ≥ 65 years, eGFR ≥ 60 mL/min/1.73 m2.
-
No detectable proteinuria at screening (negative urine dipstick);
-
MoCA score ≥ 26/30.
Exclusion Criteria
- Contraindication to MRI including claustrophobia, pregnancy or breastfeeding, cardiac pacemakers, aneurysm clips, or other MRI-incompatible devices, or inability to undergo MRI;
- Pre-existing neurological disorders known to affect cognitive function (e.g., dementia, Parkinson's disease, multiple sclerosis, epilepsy or neurodegenerative disorders);
- History of ischemic or hemorrhagic stroke and/or previous brain surgery;
- History of severe traumatic brain injury;
- Treated or untreated clinically significant depressive disorder that, in the investigator's judgment, may interfere with cognitive assessment;
- Recent hospitalization for acute events within the last 3 months, except for percutaneous transluminal angioplasty (PTA) of fistula, catheter replacement and elective hospitalizations;
- Serious acute illness within the last 3 months;
- Active solid tumors with or without metastasis;
- Inflammatory bowel disease;
- Systemic corticosteroid treatment for > 6 months at a prednisone-equivalent dose > 10 mg/day;
- Planned pregnancy during the 18-month follow-up period;
Specifically for CKD patients:
- Peritoneal dialysis;
- Kidney transplantation at enrolment;
Specifically for controls:
● Any chronic clinically significant condition, except for hypertension treated with < 3 antihypertensive drugs.
学习计划
研究是如何设计的?
设计细节
- 主要用途:其他
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Group 1
Patients with CKD stage G3 (eGFR 30-59 mL/min/1.73 m2), balanced between the two sub-stages G3a (eGFR 45-59 mL/min/1.73 m2) and G3b (eGFR 30-44 mL/min/1.73 m2) |
Montreal Cognitive Assessment Test The test include: local blood biochemistry, uremic toxin (UT) levels and blood-brain barrier (BBB) injury markers, urine dipstick, urine pregnancy test, morning urine sample, extracellular vesicle analysis, gut microbiome profiling MCI-CKD-tailored brain non-contrast MRI sequences on 3T scanners, to be acquired in the following fixed order: 3D T1-weighted MPRAGE, T2 FLAIR, Multi-echo arterial spin labelling (multi-TE ASL), Diffusion MRI, Quantitative susceptibility mapping (QSM), Multi-delay arterial spin labelling, Resting-state functional MRI (rs-fMRI) The comprehensive battery of neuropsychological tests includes: Episodic memory [assessed through Rey Auditory Verbal Learning Test (RAVLT)]; Processing speed and executive function [assessed through Trail Making Test - Part A (TMT-A) and Trail Making Test - Part B (TMT-B)]; Processing speed, attention, and working memory [assessed through Symbol Digit Modalities Test (SDMT)]; Language and executive function [assessed through Verbal Fluency Test (VFT))] Executive function assessed through Frontal Assessment Battery (FAB)] "Your Health" section, corresponding to the SF-12 questionnaire Sections specific to kidney disease excluding the first section Cognitive reserve will be assessed using the Cognitive Reserve Index questionnaire (CRIq). Symptoms of depression and anxiety will be assessed using the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7) questionnaire, respectively. Frailty will be evaluated using the Clinical Frailty Scale (CFS). The new MCI-CKD-specific quality of life questionnaire developed within the MOMENTUM project |
|
实验性的:Group 2
Patients with CKD stages G4-G5 without kidney replacement therapy (eGFR < 30 mL/min/1.73 m2) |
Montreal Cognitive Assessment Test The test include: local blood biochemistry, uremic toxin (UT) levels and blood-brain barrier (BBB) injury markers, urine dipstick, urine pregnancy test, morning urine sample, extracellular vesicle analysis, gut microbiome profiling MCI-CKD-tailored brain non-contrast MRI sequences on 3T scanners, to be acquired in the following fixed order: 3D T1-weighted MPRAGE, T2 FLAIR, Multi-echo arterial spin labelling (multi-TE ASL), Diffusion MRI, Quantitative susceptibility mapping (QSM), Multi-delay arterial spin labelling, Resting-state functional MRI (rs-fMRI) The comprehensive battery of neuropsychological tests includes: Episodic memory [assessed through Rey Auditory Verbal Learning Test (RAVLT)]; Processing speed and executive function [assessed through Trail Making Test - Part A (TMT-A) and Trail Making Test - Part B (TMT-B)]; Processing speed, attention, and working memory [assessed through Symbol Digit Modalities Test (SDMT)]; Language and executive function [assessed through Verbal Fluency Test (VFT))] Executive function assessed through Frontal Assessment Battery (FAB)] "Your Health" section, corresponding to the SF-12 questionnaire Sections specific to kidney disease excluding the first section Cognitive reserve will be assessed using the Cognitive Reserve Index questionnaire (CRIq). Symptoms of depression and anxiety will be assessed using the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7) questionnaire, respectively. Frailty will be evaluated using the Clinical Frailty Scale (CFS). The new MCI-CKD-specific quality of life questionnaire developed within the MOMENTUM project |
|
实验性的:Group 3
Patients with CKD stage G5 on chronic hemodialysis (eGFR < 15 mL/min/1.73 m2) |
Montreal Cognitive Assessment Test The test include: local blood biochemistry, uremic toxin (UT) levels and blood-brain barrier (BBB) injury markers, urine dipstick, urine pregnancy test, morning urine sample, extracellular vesicle analysis, gut microbiome profiling MCI-CKD-tailored brain non-contrast MRI sequences on 3T scanners, to be acquired in the following fixed order: 3D T1-weighted MPRAGE, T2 FLAIR, Multi-echo arterial spin labelling (multi-TE ASL), Diffusion MRI, Quantitative susceptibility mapping (QSM), Multi-delay arterial spin labelling, Resting-state functional MRI (rs-fMRI) The comprehensive battery of neuropsychological tests includes: Episodic memory [assessed through Rey Auditory Verbal Learning Test (RAVLT)]; Processing speed and executive function [assessed through Trail Making Test - Part A (TMT-A) and Trail Making Test - Part B (TMT-B)]; Processing speed, attention, and working memory [assessed through Symbol Digit Modalities Test (SDMT)]; Language and executive function [assessed through Verbal Fluency Test (VFT))] Executive function assessed through Frontal Assessment Battery (FAB)] "Your Health" section, corresponding to the SF-12 questionnaire Sections specific to kidney disease excluding the first section Cognitive reserve will be assessed using the Cognitive Reserve Index questionnaire (CRIq). Symptoms of depression and anxiety will be assessed using the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7) questionnaire, respectively. Frailty will be evaluated using the Clinical Frailty Scale (CFS). The new MCI-CKD-specific quality of life questionnaire developed within the MOMENTUM project |
|
实验性的:Group 4
Healthy controls |
Montreal Cognitive Assessment Test The test include: local blood biochemistry, uremic toxin (UT) levels and blood-brain barrier (BBB) injury markers, urine dipstick, urine pregnancy test, morning urine sample, extracellular vesicle analysis, gut microbiome profiling MCI-CKD-tailored brain non-contrast MRI sequences on 3T scanners, to be acquired in the following fixed order: 3D T1-weighted MPRAGE, T2 FLAIR, Multi-echo arterial spin labelling (multi-TE ASL), Diffusion MRI, Quantitative susceptibility mapping (QSM), Multi-delay arterial spin labelling, Resting-state functional MRI (rs-fMRI) The comprehensive battery of neuropsychological tests includes: Episodic memory [assessed through Rey Auditory Verbal Learning Test (RAVLT)]; Processing speed and executive function [assessed through Trail Making Test - Part A (TMT-A) and Trail Making Test - Part B (TMT-B)]; Processing speed, attention, and working memory [assessed through Symbol Digit Modalities Test (SDMT)]; Language and executive function [assessed through Verbal Fluency Test (VFT))] Executive function assessed through Frontal Assessment Battery (FAB)] "Your Health" section, corresponding to the SF-12 questionnaire Cognitive reserve will be assessed using the Cognitive Reserve Index questionnaire (CRIq). Symptoms of depression and anxiety will be assessed using the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7) questionnaire, respectively. Frailty will be evaluated using the Clinical Frailty Scale (CFS). |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Correlation between blood levels of the 6 predefined UTs (individually and in combination) and the presence and severity of cognitive impairment, within each CKD group separately.
大体时间:Baseline (Visit 2, Day 0)
|
Correlation coefficient (e.g., Pearson's r or Spearman's rho). The coefficient is computed for each of the 6 UTs and for the combination, within each CKD group separately. |
Baseline (Visit 2, Day 0)
|
合作者和调查者
调查人员
- 研究主任:Norberto Perico, M.D.、Istituto Di Ricerche Farmacologiche Mario Negri
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- MOMENTUM
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.